Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum

In a report released today, Albert Lowe from Craig-Hallum maintained a Buy rating on Actuate Therapeutics, Inc.. The company’s shares closed yesterday at $6.26.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
• Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

Lowe covers the Healthcare sector, focusing on stocks such as Actuate Therapeutics, Inc., Rezolute, and Eupraxia Pharmaceuticals. According to TipRanks, Lowe has an average return of 18.4% and a 65.12% success rate on recommended stocks.

Actuate Therapeutics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $26.00.

Based on Actuate Therapeutics, Inc.’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.32 million. In comparison, last year the company had a GAAP net loss of $8.3 million

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACTU in relation to earlier this year.